Compared with conventional bivalent BsAbs, the monovalent construct reprograms TfR-mediated endocytosis and recycling to achieve both efficient BBB transit and anti-angiogenic activity, demonstrating superior potential for brain-tumor therapy. This evidence concerns the gene TFRC and brain neoplasm.